Bermekimab
From WikiMD's WELLNESSPEDIA
| Bermekimab | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | intravenous |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 1401965-15-8 |
| PubChem | |
| DrugBank | |
| ChemSpider | none |
| KEGG | D11253 |
Bermekimab[1] (MABp1, trade name Xilonix) is a human monoclonal antibody of IgG1k isotype targeting Interleukin 1 alpha (IL1A).[2] As of
2017[update][[Category:Articles containing potentially dated statements from Expression error: Unexpected < operator.]], bermekimab is in phase III clinical trials as an immunotherapy for colorectal cancer[3] and as of September 2018 in phase II clinical trials for the treatment of atopic dermatitis.[4]
Bermekimab is being developed by XBiotech Inc.[5]
References[edit]
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Bermekimab, American Medical Association.
- ↑ "MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study".The Lancet Oncology.May 2014;15(6)
- 656-66.doi:10.1016/S1470-2045(14)70155-X.Full text.
- ↑ A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer (XCITE)(link). ClinicalTrials.gov. U.S. National Institutes of Health.
- ↑ A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis(link). ClinicalTrials.gov. U.S. National Institutes of Health.
- ↑ Xilonix™ True Human™ monoclonal antibody by Xbiotech oncology(link). www.xbiotech.com. XBiotech.
 | This medical article is a stub. You can help WikiMD by expanding the page. |
